By a vote of 13-10, an FDA advisory panel voted to approve molnupiravir, Merck’s new treatment for COVID-19:

This was a “surprisingly close vote”:

Shouldn’t it be a bigger deal that the drug barely passed this step?

The panel said the drug “should be restricted to high-risk unvaccinated adults, as in the clinical trial”:

The panel’s concerns “included male fertility and birth defects, bone growth, embryonic loss, and enhancement of escape mutations”:

Merck is recommending that pregnant women do not take the drug:

And it’s not being recommended for children:


Tags: Merck